Post

4DMT’s CF gene therapy posts early cues for improving patient outcomes

The use of 4D Molecular Therapeutics’ (4DMT) aerosolised gene therapy 4D-710 has improved the quality-of-life and spirometry-measured outcomes in three …

Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as …

GenScript ProBio and CCS partner for cell and gene therapies development

GenScript ProBio has collaborated with the New York Blood Center Enterprises’ business unit, called Comprehensive Cell Solutions (CCS), to accelerate …

UK’s MHRA expands approval for Merz Therapeutics’ XEOMIN

The UK’s medicines and healthcare products regulatory agency (MHRA) has granted approval for a new indication for Merz Therapeutics’ XEOMIN …

Mendus and NorthX to establish cell therapy manufacturing unit

Mendus has entered an alliance with NorthX Biologics to co-establish a cell therapy manufacturing unit for its lead asset, vididencel, …